



Dear National Coordinating Investigators,

Welcome to the second edition of the Garfield VTE Newsletter. As of the first week in June, we have recruited 1074 patients globally.

Global Enrolment : By Country



GARFIELD-VTE Global Recruitment (5 Jun 2015) – LPFV Dec 2015




We are pleased to share with you the preliminary baseline results on patient characteristics, planned treatment, prior treatment and risk factors for the first 1,000 patients:

Global News and Announcements

- The first publication on the Garfield VTE study is planned for the first quarter of 2016 and we hope to include as many patients as we can in the analysis. In order to have meaningful results from each country, we will need to have **at least cohort 1 completed by December 2015**. Your help in encouraging the sites in your country to achieve this will be much appreciated.
- Some countries have already started to organise local meetings by teleconference to identify barriers to enrolment. We will be contacting you shortly to discuss the feasibility and logistics of these local meetings in your country. In addition, as summer is approaching in most countries, many site personnel are planning their summer vacation. Please remind the sites to ensure that there is sufficient cover at the sites to ensure that enrolment is not adversely impacted during these few months.


Proportion of patients with DVT and PE at baseline




Project Team at TRI

Gloria Kayani (Chief Operating Officer), Pearl Kho (Global Project Manager), Richard Coles (Regional Project Manager, Americas, Asia), Elizabeth Demmisse (Regional Project Manager, EMEA), Sofia Fernandez (Research Coordinator, UK, France, Spain), Luz Angela Gomez (Clinical Trial Administrator).


Planned treatment




Treatment at baseline



Risk factors for VTE (568 patients had at least one risk factor)



GARFIELD-VTE – Recruitment in Italy



Site Recruitment

PI	Site #	SIV	Projection during IMVs	Actual Enrolment per SVR	Actual Enrolment per EDC
Ageno, Walter	ITA0038	29-Jan-15	40	7	5
Agnelli, Giancarlo	ITA0039	05-Feb-15	90	12	1
Berni, Andrea	ITA0040	28-Apr-15	NA	0	0
Cappelli, Roberto	ITA0041	26-Feb-15	25	6	6
Cattaneo, Marco	ITA0042	24-Mar-15	10	1	1
Cosmi, Franco	ITA0043	17-Feb-15	30	6	6
D'Angelo, Armando	ITA0044	30-Apr-15	NA	2	2
Ferrini, Piera Maria	ITA0045	27-Mar-15	25	0	0
Imberti, Davide	ITA0046	29-Apr-15	30	4	4
Lodigiani, Corrado	ITA0047	30-Mar-15	64	0	0
Mazzone, Antonino	ITA0048	TBS	N/A		
Moia, Marco	ITA0049	05-May-15	15	0	0
Pizzini, Attilia	ITA0050	29-Apr-15	30	0	0
Poli, Daniela	ITA0051	27-Jan-15	15	0	0
Porreca, Ettore	ITA0052	23-Apr-15	40	0	0
Prisco, Domenico	ITA0053	09-Mar-15	40	1	1
Santoro, Rita	ITA0054	30-Mar-15	30	10	10
Tirafferri, Eros	ITA0055	TBS	N/A		
Tosetto, Alberto	ITA0056	12-Mar-15	20	0	0

Clarification of Inclusion and Exclusion Criteria:

(1) Patients who have a short life expectancy, for example, less than 6 months should be excluded

(2) Patients who have been treated for previous AF rather than VTE should be excluded

Study Timelines

Global recruitment is currently behind target, all efforts should be made to ensure that at least Cohort 1 is completed by December

Electronic Data Capture System (Clinpal)

On-line tutorial will be available in July to familiarise users with the system

Project Team at TRI

Gloria Kayani (Chief Operating Officer), Pearl Kho (Global Project Manager), Richard Coles (Regional Project Manager, Americas, Asia), Elizabeth Demisse (Regional Project Manager, EMEA), Sofia Fernandez (Research Coordinator, UK, France, Spain), Luz Angela Gomez (Clinical Trial Administrator).

